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Abstract
Background: Exercise interventions during adjuvant cancer therapy have been shown to increase functional
capacity, relieve fatigue and distress and may assist rates of chemotherapy completion. These studies have been
limited to breast, gastric and mixed cancer groups and it is not yet known if a similar intervention is even feasible
among women with ovarian cancer. We aimed to assess safety, feasibility and potential effect of a walking
intervention in women undergoing chemotherapy for ovarian cancer.
Methods: Women newly diagnosed with ovarian cancer were recruited to participate in an individualised walking
intervention throughout chemotherapy and were assessed pre- and post-intervention. Feasibility measures included
session adherence, compliance with exercise physiologist prescribed walking targets and self-reported program
acceptability. Changes in objective physical functioning (6-minute walk test), self-reported distress (Hospital Anxiety
and Depression Scale), symptoms (Memorial Symptom Assessment Scale - Physical) and quality of life (Functional
Assessment of Cancer Therapy - Ovarian) were calculated, and chemotherapy completion and adverse intervention
effects recorded.
Results: Seventeen women were enrolled (63% recruitment rate). Mean age was 60 years (SD = 8 years), 88% were
diagnosed with FIGO stage III or IV disease, 14 women underwent adjuvant and three neo-adjuvant chemotherapy.
On average, women adhered to > 80% of their intervention sessions and complied with 76% of their walking
targets, with the majority walking four days a week at moderate intensity for 30 minutes per session. Meaningful
improvements were found in physical functioning, physical symptoms, physical well-being and ovarian cancer-
specific quality of life. Most women (76%) completed ≥85% of their planned chemotherapy dose. There were no
withdrawals or serious adverse events and all women reported the program as being helpful.
Conclusions: These positive preliminary results suggest that this walking intervention for women receiving
chemotherapy for ovarian cancer is safe, feasible and acceptable and could be used in development of future work.
Trial registration: ACTRN12609000252213
Keywords: Ovarian neoplasm, exercise, chemotherapy, feasibility
Background
Ovarian cancer is the second most common gynaecolo-
gic malignancy [1] with treatment typically involving
radical cytoreductive surgery and chemotherapy.
Women with ovarian cancer differ from other cancer
groups due to their older age, predominantly late stage
diagnosis, poorer prognosis, treatment involving major
abdominal surgery and different chemotherapy agents/
doses/regimens with significant side-effects [2]. Overall,
up to 90% of women receiving chemotherapy for ovarian
cancer experience nausea, difficulty sleeping and pain
[3], and the presence of these side effects has been asso-
ciated with reduced physical function [4] and/or prema-
ture chemotherapy cessation [5]. Anxiety and depression
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are also common during treatment for ovarian cancer,
with higher rates than those reported in other cancer
cohorts [6]. The presence of these physical and psycho-
logical concerns likely contribute to low levels of quality
of life (QoL) observed during chemotherapy for ovarian
cancer [7] and may be associated with reduction of
planned chemotherapy dose [8] and overall survival [7].
In a previous study, up to one-third of women
receiving treatment for ovarian cancer were not able to
complete their prescribed first-line chemotherapy
course; specifically, approximately 10% required a dose
reduction, replacement or removal of an agent and 6%
ceased treatment altogether [3]. Intravenous che-
motherapy completion rates using cisplatin and pacli-
taxel in advanced stage ovarian cancer have been
reported to range between 83% [9] and 86% [10].
Others observed changes to chemotherapy schedules in
56% to 91% of colon or breast cancer patients [11,12].
This is important because, among patients with breast
cancer changes to their intended chemotherapy
courses or doses reduced response rates to treatment
from 68% to 30% [13].
Exercise has been suggested as a means of attenuating
physical and psychological side-effects of cancer treat-
ment. A recent meta-analysis involving 33 studies of
exercise intervention studies conducted during cancer
treatment found that the majority of interventions
resulted in improved physical activity, aerobic fitness,
and QoL, as well as reductions in anxiety, body fat per-
centage, and body weight [14]. The interventions evalu-
ated commonly involved aerobic or combined aerobic/
resistance training (n = 29), at a moderate to vigorous
intensity (n = 20), three to five times per week (n = 21),
for a duration of 20-45 minutes per session (n = 18),
and for at least five weeks. The majority of the studies
(n = 26) enrolled women with breast cancer, with only
one study including women with ovarian cancer. The
potential for exercise to influence chemotherapy com-
pletion rates has been considered in only one study to
date [15]. Women were assigned to a supervised aerobic
exercise intervention (three times per week, 15-45 min-
utes duration, 60-80% VO2max) or supervised resistance
training intervention (three times per week performing
8-12 repetitions for two sets of nine different exercises)
conducted throughout the duration of chemotherapy,
respectively. Compared to standard care (66%), 74% and
78% of women in the intervention groups completed
their prescribed chemotherapy. These results suggest
that exercise during chemotherapy may improve treat-
ment adherence, and are worthy of further investigation.
The benefits of individualised exercise programs for all
cancer patients in minimising risk of injury and optimis-
ing individual gain has been highlighted in the Austra-
lian Exercise and Sport Science Association position
stand on optimising cancer outcomes through exercise
[16]. To date, women with ovarian cancer have not been
the focus of randomised controlled trials involving exer-
cise intervention. A recent publication reported on the
feasibility of a lifestyle counseling intervention, where
women with ovarian cancer were given generic advice to
stay as active as their energy level allowed during che-
motherapy (n = 27)[17]. However, there have been no
published individualised exercise intervention studies
involving a heterogeneous group of women with ovarian
cancer. The main purpose of this study was therefore to
assess the safety and feasibility of an individualised walk-
ing intervention in women undergoing chemotherapy
treatment for ovarian cancer. We also describe pre-post
intervention changes in physical functioning, anxiety,
depression, physical symptoms and QoL, and record
chemotherapy completion rates.
Methods
This non-randomised phase 2 trial assessed safety and
feasibility of a walking intervention prior and after the
completion of chemotherapy. Pre-intervention assess-
ment was conducted prior to the first or second cycle of
neo-adjuvant or adjuvant chemotherapy, while the post-
intervention assessment was conducted three weeks
after the last dose of chemotherapy. Ethics approval was
obtained from Queensland Institute of Medical Research
(P1222), Queensland University of Technology
(0900000333) and Royal Brisbane and Women’s Hospi-
tal (HREC/08/QRBW/19).
Eligible patients were those living in Queensland, Aus-
tralia and treated at Royal Brisbane and Women’s Hos-
pital for invasive ovarian, peritoneal or fallopian tube
cancer between June 2009 and September 2010. They
were about to start their first or second cycle of adju-
vant or neo-adjuvant chemotherapy; aged 18 years or
older; able to complete questionnaires in English and
provide informed consent. Women who were identified
by their gynaecological oncologist as too sick to partici-
pate or who had a prior malignancy (excluding non-
melanoma skin cancers) within the last five years were
excluded. Under the original study protocol, where
intervention delivery was restricted to face-to-face con-
tact, 16 out of 28 women (57%) were ineligible because
they lived > 60 kms from the hospital, significantly influ-
encing our ability to recruit women into the study. Con-
sequently, the mode by which the intervention could be
delivered was broadened to allow for telephone-delivery
and as such the residence criterion was removed.
Prior to the commencement of the intervention, demo-
graphic data including age, marital status, education and
health insurance status (public or private), were obtained
from consenting women via self-report. Clinical informa-
tion on stage, histology and chemotherapy regimen
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(according to the classifications used by the International
Federation of Gynecology and Obstetrics FIGO) were
abstracted from the medical records.
Participants were given an educational booklet related
to the walking intervention, which included topics such
as how to monitor walking intensity, when not to walk,
and monitoring changes in treatment-related side-
effects. Due to the nature of the study population, the
weekly walking prescription (frequency, intensity and
duration) was individualised by an exercise physiologist
(allied health professional with tertiary training in exer-
cise science and with additional specialist training in
exercise prescription for cancer patients). Initial targets
were based on pre-intervention assessment of physical
functioning and level of physical activity. Sedentary
women were instructed to begin by taking frequent
(most days), but lower-intensity, shorter duration (10
minute) walks. Active women were initially instructed to
maintain their current number of sessions and increase
firstly the duration and later the intensity. All partici-
pants were instructed to record details of their walking
activity using a logbook. Participants met with the exer-
cise physiologist once per week, either face-to-face (for
women living within 60 km of the treating hospital) or
over the telephone (for regional/rural women) for the
duration of their chemotherapy treatment. For the face-
to-face group this session included a supervised walk
with the exercise physiologist. During these weekly ses-
sions, presence and change to treatment-related side-
effects were identified, barriers to walking were dis-
cussed and resolved when possible, details of previous
week’s walking sessions were discussed, and based on
this the subsequent week’s walking targets were pre-
scribed per individual. The weekly session duration with
the exercise physiologist was between 20-60 minutes,
with longer sessions typically required in the earlier
weeks of the intervention to ensure the topics within
the education booklet were discussed. Given the pilot
nature of this work, the mode of contact with the exer-
cise physiologist was flexible. For example, telephone
contact was allowed for local women when face-to-face
sessions were difficult to arrange and face-to-face con-
tact was provided to rural women when they returned
to hospital for follow-up care or treatment.
Recruitment rate was defined by the number of con-
senting, divided by the number of eligible women
approached to participate. Retention was determined by
the number of participants who completed the pre- and
post-intervention testing. Adherence was ascertained by
the number of completed sessions relative to the num-
ber of scheduled sessions with the exercise physiologist,
while compliance was determined by comparing exercise
physiologist prescribed walking duration, frequency and
intensity with details recorded in participants’ completed
walking logs. Acceptability of the walking program was
assessed post-intervention using a written evaluation
form, which asked participants to rate on a seven-point
Likert-scale how helpful the program, the education
booklet, and the exercise physiologist sessions were. Par-
ticipants were also asked to indicate how they felt about
participating in the walking program during their che-
motherapy treatment. Participant-reported adverse
effects (safety) were pre-defined as any unfavorable
change from ‘normal’ condition that limited everyday
living.
Physical functioning was measured using the six-min-
ute walk test (6MWT), which has strong test-retest
reliability (intraclass correlation = 0.97) [18]. The test
requires participants to walk along a flat, 10-metre
length, straight pathway for six continuous minutes at a
comfortable pace. Distance travelled by the test cessa-
tion was recorded. Anxiety and depression were mea-
sured by the validated Hospital Anxiety and Depression
Scale (HADS) [19]. The HADS is a self-rated instrument
containing two subscales, anxiety and depression (coeffi-
cient alphas of 0.93 and 0.90, respectively), with seven
items per subscale, using a 4-point Likert scale. Symp-
toms were measured using the physical symptom sub-
scale of the validated Memorial Symptom Assessment
Scale (MSAS-PHYS)(Cronbach’s alpha = 0.88) [20]. This
scale evaluates frequency, severity and distress of 12
treatment-related symptoms over the previous seven
days. Frequency and distress are rated on a 5-point
Likert scale, while the severity dimension is rated on a
4-point Likert scale, ranging from one to four. Quality
of life was measured using the Functional Assessment of
Cancer Therapy - Ovary (FACT-O) [21]. The FACT-O
includes 39 items to measure five wellbeing domains
(physical, social/family, emotional, functional and ovar-
ian cancer-specific concerns) over the past seven days,
on a 5-point Likert scale. This instrument has under-
gone extensive reliability and validity testing showing
that internal consistency and test-retest reliability is ade-
quate [21]. The HADS, MSAS-PHYS and FACT-O were
all participant-administered. Chemotherapy completion
information was abstracted from medical records by the
research nurse. As is convention, the relative dose inten-
sity (RDI) of each chemotherapy agent was calculated by
expressing the total delivered dose per unit time as a
percentage of the initial target dose, then each agent
(commonly two agents prescribed) was added together
and divided by the number of agents to get a total RDI
[22].
We pre-defined acceptable walking intervention
adherence as women participating in 75% or more of
the scheduled weekly sessions with the exercise physiol-
ogist. Participants were considered compliant to the pre-
scribed walking intervention when they achieved two
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out of three exercise prescription targets (frequency,
intensity and duration). Pre- and post-intervention con-
tinuous outcomes (physical functioning, anxiety, depres-
sion, symptoms and QoL) were summarised using
median and ranges scores. Pre- and post-intervention
data were compared statistically using Wilcoxon Signed
Ranked tests, with statistical significance set at p < 0.05.
Results were analysed using SPSS 16.0. A priori defined
clinically important changes (±) in outcomes were as
follows: ≥ 54 meters for the 6MWT [23], 1.5 points for
HADS scores [24], 0.2 for MSAS-PHYS score [25], 2 for
the FACT-O subscales, 3 for ovarian cancer-specific
concerns and 5 for the overall FACT-O scale [26]. Pre-
defined acceptable chemotherapy completion was based
on a previously applied criterion of 85% or more of
initially planned chemotherapy dose [15].
Results
Recruitment
Sixty-two women presenting with possible ovarian can-
cer at the participating hospital were screened over
approximately 15 months (Figure 1). Nineteen women
were ineligible as a consequence of having borderline
tumors (n = 6), not receiving chemotherapy (n = 3),
being considered too sick to participate by their gynae-
cologist (n = 5) or other reasons (n = 5). Of the 27 eligi-
ble women, 17 (63%) consented to participate, eight of
whom lived locally and therefore received weekly con-
tacts with the exercise physiologist on a face-to-face
basis, while the remaining nine women, received their
weekly contacts over the telephone.
Sample characteristics
Participant’s pre-intervention demographic and clinical
characteristics are summarised in Table 1. Women
were aged between 44-71 years (mean 60.4 years).
Approximately half (58%) were married or in a de
facto relationship, all had at least a high school educa-
tion, and most (76%) did not have private health insur-
ance. The majority of women were diagnosed with a
serous cell type on histological diagnosis (82%) and
FIGO stage III or IV disease (88%). Prescribed che-
motherapy varied; the most common regimen being
six times three-weekly cycles of carboplatin and
BRISBANE WOMEN ONLY 
 
8th June – 27th October 2009  
RBWH women assessed for eligibility 
(n=28) 
Ineligible = 86%: 
 Borderline tumour (n=3) 
 <18 years (n=2) 
 Unable to communicate in English (n=1) 
 No chemotherapy (n=2) 
 Live too far away for regular face-to-face visits (n=16) 
Excluded = 4% 
 No consent to contact – too sick (n=1) 
Ineligible = 18%: 
 Borderline tumour (n=3) 
 Recent prior malignancy (n=1) 
 Cognitive impairment (n=1) 
 No chemotherapy (n=1) 
Excluded = 12% 
 No consent to contact – too sick (n=4) 
ALL WOMEN 
 
28th October – 14th September 2010  
RBWH women assessed for eligibility 
(n=34) 
RECRUITMENT 
Recruitment rate = 83%: 
 Allocated to intervention (n=17) 
 Refused to participate (n=10) 
FOLLOW-UP 
Retention rate = 100%: 
 Analysis (n=17) 
Figure 1 Participant recruitment, allocation and retention.
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paclitaxel (59%). Chemotherapy was administered
intravenously (with or without the addition of intraper-
itoneal delivery) with three women receiving neo-adju-
vant therapy and 14 adjuvant chemotherapy.
Compared to women with ovarian cancer listed in the
population-based gynaecological cancer registry (n =
1,286) [27], in this pilot study, there was a higher pro-
portion of women in the 60-69 year age bracket (47%
compared with 23%), a higher proportion of women
with FIGO stage III or IV disease (88% compared with
50%), and all women received surgery and chemother-
apy compared to only 75% of women from the registry.
Feasibility and safety
No withdrawals were recorded during the walking inter-
vention (100% retention). The number of weeks under
active chemotherapy (and therefore possible exercise
physiologist sessions) ranged from 11 to 21 weeks.
Overall group adherence was 90% (range 55% to 100%),
with 14 of 17 women (82%) participating in at least 75%
of scheduled face-to-face or telephone intervention ses-
sions. Participants missed a median of two sessions
(range 0-8), most commonly due to cancer treatment-
related hospitalization, holidays, or being too ill. In addi-
tion, for Brisbane women (n = 8), 17 out of 136 face-to-
face sessions were changed to telephone sessions (each
local woman had one to five sessions over the tele-
phone), while one of the nine women living more than
60 km from hospital had 11 face-to-face sessions as they
coincided with treatment.
The median and range of frequency (number of days),
intensity (rating of perceived exertion scale) and dura-
tion (minutes) of walking sessions undertaken each
week for each woman are illustrated in Figure 2. On
average women walked four days a week (range 0-7) at
moderate intensity for 30 minutes per session (range
22-57 minutes). Overall, compliance with at least two
out of three individual weekly prescription targets (fre-
quency, intensity and duration) ranged from 42% to
94%, with a median of 88%.
Sixteen women (94%) completed and returned the
intervention evaluation, all of whom found the program
to be either ‘helpful’ or ‘very helpful’. The vast majority
(81%) rated the sessions with the exercise physiologist as
‘very helpful’, while 75% considered the program to be
‘excellent’. One minor adverse event, a fall causing minor
cuts and bruises, occurred (no major adverse event).
Clinical effects
Clinically important improvements were observed in
physical functioning, physical symptoms, physical and
ovarian-specific QoL between pre- and post-intervention
(Table 2). Improvements were also observed in seven
out of twelve physical symptoms including lack of appe-
tite, pain, feeling drowsy, constipation, dry mouth, nau-
sea and weight loss. No change was found in anxiety or
depression or in the social, emotional and functional
wellbeing QoL subscales.
Table 1 Demographic and clinical characteristics of
participants at baseline assessment (n = 17)
Characteristics
Demographic
Age at baseline, mean (SD) 60 (8)
N %
Marital status
Never married 3 18
De facto/married 10 58
Separated/divorced 3 18
Widowed 1 6
Education level
University 2 12
Technical/trade 2 12
Secondary (grade 10-12) 13 76
Private health insurance
No 13 76
Yes 4 24
Body mass index categories*
Underweight (< 18.5 kg/m2) 2 20
Healthy weight (18.5-24.9 kg/m2) 4 40
Overweight (25-29.9 kg/m2) 2 20
Obese (30+ kg/m2) 2 20
Clinical
Primary cancer site
Ovary 13 76
Peritoneum 4 24
Histology
Endometrioid 1 6
Serous and other 14 82
Mucinous 1 6
Unknown 1 6
Disease stage (FIGO)
I 1 6
II 1 6
III 11 64
IV 4 24
Chemotherapy regimen
6 × 3-weekly Carboplatin + Paclitaxel 10 59
Other 7 41
Chemotherapy route
Intravenous 9 53
Intravenous + Intraperitoneal 8 47
Chemotherapy course
Adjuvant 14 82
Neo-adjuvant 3 18
Body mass index not collected for seven regional women due to inaccessibility;*
Not known; NK
International Federation of Gynecology and Obstetrics; FIGO
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All women received all of their planned chemotherapy
cycles. Relative dose intensity received of planned che-
motherapy ranged from 67% to 100% (median 92%).
Thirteen out of 17 (76%) women had an RDI equal to
or above 85% of their scheduled dose.
Discussion
Importantly, results suggest participating in an individu-
ally tailored face-to-face or telephone delivered walking
program during chemotherapy for ovarian cancer is safe
and feasible. Retention (100%), adherence (82%) and
Figure 2 Box plots of frequency, intensity and duration of walking achieved throughout the intervention for each participant
(assessed by self-report exercise log; n = 17). Figure 2 (A): Frequency (number of days) per week. Figure 2 (B): Intensity level (rating of
perceived exertion scale) per session. Figure 2 (C): Duration (minutes) of walking per session. Footnote: Symbols: box = 1st & 3rd quartiles, line
inside box = median, whisker length = minimum & maximum (range).
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compliance rates (88%) in this pilot were high and com-
pare favorably with feasibility data from previous studies
of home-based exercise conducted with patients under-
going chemotherapy for other cancers (adherence 60-
90%) [4,28]. Our high rates may have been related to
the close monitoring (weekly sessions with the exercise
physiologist), personalised feedback, or on-going sup-
port provided by the exercise physiologist. The home-
based nature of the intervention, allowing the partici-
pants to undertake sessions at times most convenient to
them may also have contributed. In addition, and in
contrast to most other interventions, our moderate
exercise was achieved through walking, reported to be
the preferred type of aerobic-exercise for women with
ovarian cancer [29].
While national and international evidence-based
guidelines on the participation in exercise during and
following treatment for cancer exist, few previous exer-
cise interventions have involved women with ovarian
cancer. As a consequence, it was a considerable chal-
lenge to mount this pilot study, given the prevailing
assumption that exercise intervention is not appropri-
ate for women undergoing chemotherapy for ovarian
cancer. The majority of women in this study walked
on average four days a week, at moderate intensity, for
approximately 30 minutes per session, throughout the
duration of their chemotherapy. Treatment-related
side-effects presented barriers to participating in the
walking intervention, however, the participant and
exercise physiologist together identified ways in which
these could be overcome. For example, the walking
route was modified to ensure symptoms such as diar-
rhea or nausea could be accommodated. Importantly,
not only were woman able to participate fully in the
walking intervention, but they also found the program
highly acceptable.
Participating in the walking intervention was asso-
ciated with improvements in physical functioning, physi-
cal symptoms and ovarian cancer-specific QoL. While
the absence of a randomised control group prevents the
establishment of a causal relationship and the small
sample size means that some changes did not reach sta-
tistical significance, the changes observed are similar to
those reported from aerobic exercise interventions in
women with breast cancer [28]. Further, results from
cancer studies suggest that patients typically decline in
physical function and QoL during chemotherapy, and
report symptoms of high frequency and severity [30].
Therefore, it seems plausible that a walking intervention
during chemotherapy may prevent declines and reduce
the impact of symptoms.
Three quarters (n = 13) of the women in this study
received greater than or equal to 85% of their planned
chemotherapy dose (median 92%) and all women com-
pleted all of their planned cycles. It is difficult to com-
pare these data with other reports of chemotherapy
completion in ovarian cancer as previous studies have
been drug trials that deliver non-standard chemotherapy
regimens and limit their samples to women with
advance disease [9,10]. As such, a larger sample with
randomised controlled data is needed to confirm
whether exercise can assist in improving chemotherapy
completion rates.
Conclusion
This is the first individualised exercise intervention
study that focuses entirely on women with ovarian
cancer whilst undergoing chemotherapy. Although this
is a non-randomised study with a relatively small sam-
ple size, important preliminary findings have been
derived from this work. Despite the intervention being
conducted during a time typically associated with ele-
vated distress and treatment side-effects that are often
severe enough to alter or cease chemotherapy prescrip-
tion, women perceived the program as helpful. Most
importantly, the program was safe and feasible and
showed promise for reducing some symptoms, and
optimising physical function and QoL during che-
motherapy. These results provide the necessary
Table 2 Outcome measures assessed pre- and post-
participation in the walking intervention (n = 17)
Outcome Baseline Follow-up
Median
(min, max)
Median
(min, max)
P-
valuea
Physical functioningb 332 (266,
356)
395 (356, 460)* 0.01
Anxiety 4 (1, 15) 4 (0, 16) 0.63
Depression 3 (0, 16) 4 (0, 13) 0.16
Physical symptoms 1.06 (0.0,
2.33)
0.60 (0.06, 2.06)
*
0.14
Quality of lifec (FACT-O) 109 (72, 146) 113 (67, 148) 0.10
Physical wellbeing 18 (12, 27) 23 (12.0, 28)* 0.08
Social wellbeing 23 (12, 28) 22 (8, 28) 0.11
Emotional wellbeing 20 (7, 24) 21 (10, 24) 0.29
Functional wellbeing 19 (7, 28) 19 (7, 28) 0.02
Ovarian-specific
concerns
31 (20, 41) 36 (21, 44)* 0.04
Clinically meaningful change;*
Wilcoxon signed ranked test used for analysis;a
Physical functioning is measured in metres (m)
Physical functioning data not collected for seven regional women due to
inaccessibility;b
A higher score indicates a better quality of life;c
Functional Assessment of Cancer Therapy-Ovary; FACT-O
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platform from which a larger, randomised controlled
trial can be developed.
Acknowledgements
Ms Newton is supported by a postgraduate scholarship award from
Queensland University of Technology. We gratefully acknowledge the
funding contribution from the Gynaecological Cancer Society, as well as the
financial support provided by Dr Hayes (National Breast Cancer Foundation
Early Career Fellowship), Drs Webb, Whiteman & Green (NHMRC Program
Grant) and Dr Beesley (NHMRC Early Career Fellowship). We would also like
to thank Sue Brown and Judy Eddy for assistance with recruitment and
reviewing of medical records, plus the women who so kindly participated in
this research.
Author details
1School of Public Health, Queensland University of Technology, Brisbane,
Australia. 2Gynaecological Cancers Group, Queensland Institute of Medical
Research, Brisbane, Australia. 3Queensland Centre for Gynaecologic
Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Australia. 4School
of Population Health, The University of Queensland, Brisbane, Australia.
5Department of Medical Oncology, Royal Brisbane and Women’s Hospital,
Brisbane, Australia. 6Centre for Applied Health Economics, Griffith University,
Brisbane, Australia.
Authors’ contributions
MN, VB and SH had full access to all the data in the study and take
responsibility for the integrity of the data and accuracy of data analysis. VB,
SH, MJ, PW, EE, LG and DW initiated study concept and design. In addition
clinician, AO, specialises in gynaecological oncology and enabled participant
recruitment. Data acquisition was conducted by MN. Analysis and
interpretation of data was carried out by MN, SH, VB and MJ. MN, SH, VB
and MJ drafted the manuscript and AO, PW, EE, LG and DW provided critical
revisions and important intellectual content. Study supervision and funding
was supplied by SC, MJ, VB and PW. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 June 2011 Accepted: 8 September 2011
Published: 8 September 2011
References
1. Australian Institute of Health and Welfare (AIHW) & Australasian Association
of Cancer Registries (AACR): Cancer in Australia 2000. Canberra: AIHW
(Cancer Series no 23); 2003, AIHW Cat. No. CAN 18.
2. Quasthoff S, Hartung H: Chemotherapy-induced peripheral neuropathy. J
Neurol 2002, 249:9-17.
3. Gordon LG, Scuffham PA, Beesley VL, Green AC, DeFazio A, Wyld DK,
Clavarino AM, Australian Ovarian Cancer Study Group, Webb PM: Outcomes
and related medical costs for women with ovarian cancer in Australia: a
patient-level analysis over 21/2 years. Int J Gynecol Cancer 2010,
20:757-765.
4. Schwartz A: Physical activity after a cancer diagnosis: psychosocial
outcomes. Cancer Invest 2004, 22(1):82-92.
5. Olsen CM, Bain CJ, Jordan S, Nagle C, Green A, Whiteman D, Webb P,
Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer
Study Group: Recreational Physical Activity and Epithelial Ovarian Cancer:
A Case-Control Study, Systematic Review, and Meta-analysis. Cancer
Epidemiol Biomarkers Prev 2007, 16(11):2321-2330.
6. Bodurka-Bevers D, Basen-Engquist K, Carmack C, Fitzgerald M, Wolf J, de
Moor C, Gershenson D: Depression, Anxiety, and Quality of Life in
Patients with Epithelial Ovarian Cancer. Gynecol Oncol 2000, 78:302-308.
7. Wenzel L, Huang H, Armstrong D, Walker J, Cella D: Health-related quality
of life during and after intraperitoneal versus intravenous chemotherapy
for optimally debulked ovarian cancer: a Gynecologic Oncology Group
Study. J Clin Oncol 2007, 25:437-443.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis T, McFadden ET,
Carbone P: Toxicity and response criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 1982, 5:649-655.
9. Markman M, Bundy B, Alberts D, Clark-Pearson DL, Carson LF, Wadler S,
Sickel J: Phase III Trial of Standard-Dose Intravenous Cisplatin Plus
Paclitaxel Versus Moderately High-Dose Carboplatin Followed by
Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume
Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic
Oncology Group, Southwestern Oncology Group, and Eastern
Cooperative Oncology Group. J Clin Oncol 2001, 19(4):1001-1007.
10. Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L,
Walker J, Burger R, for the Gynecologic Oncology Group: Intraperitoneal
cisplatin and paclitaxel in ovarian cancer. New Eng J Med 2006,
354(1):34-43.
11. Hirria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C: Factor
influencing treatment patterns of breast cancer patients age 75 and
older. Crit Rev Oncol Hematol 2003, 46:121-126.
12. Law CC, Fu YT: Postoperative adjuvant 5-Fluororuacil plus levamisole
chemotherapy for stage III colon carcinoma: 7-year experience in a
single institution. J Hong Kong College Rad 2002, 5:97-104.
13. D’hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van
Oosterom A: Safety and efficacy of weekly docetaxel in frail and/or
elderly patients with metastatic breast cancer: a phase II study.
Anticancer Drug 2004, 15:341-346.
14. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH: An update of
controlled physical activity trials in cancer survivors: a systematic review
and meta-analysis. J Cancer Surviv 2010, 4:87-100.
15. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid R, Friedenreich C,
Ladha A, Proulx C, Vallance J, Lane K, Yasui Y, McKenzie D: Effects of
aerobic and resistance exercise in breast cancer patients receiving
adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin
Oncol 2007, 25:4396-4404.
16. Hayes SC, Spence RR, Galvao DA, Newton R: Australian Association for
Exercise and Sport Science position stand: optimising cancer outcomes
through exercise. J Sci Med Sport 2009, 12:428-434.
17. Von Gruenigen V, Frasure H, Kavanagh M, Lerner E, Waggoner SE,
Courneya KS: Feasibility of a lifestyle intervention for ovarian cancer
patients receiving adjuvant chemotherapy. Gynecol Oncol 2011.
18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit
Care Med 2002, 166:111-117.
19. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta
Psychiatr Scand 1983, 67(6):361-370.
20. Chang V, Hwang S, Feuerman M, Kasimis B, Thaler H: The Memorial
Symptom Assessment Scale Short Form (MSAS-SF) Validity and
Reliability. Cancer 2000, 89:1162-1171.
21. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M, Webster K, Cella D, Hu S,
Gershenson D: Reliability and validity of the functional assessment of
cancer therapy - Ovarian. J Clin Oncol 2001, 19:1809-1817.
22. Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M,
Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T,
Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M: Impact of relative dose
intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival
in diffuse large B-cell lymphoma. J Exper Clin Can Res 2009, 28:116.
23. Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE: The six-minute
walk test: a useful metric for the cardiopulmonary patient. Intern Med J
2009, 39(8):495-501.
24. Puhan M, Frey M, Büchi S, Schünemann H: The minimal important
difference of the hospital anxiety and depression scale in patients with
chronic obstructive pulmonary disease. Health Qual Life Outcome 2008,
6:46.
25. Walker P: Which symptoms are prevalent in patients with recurrent
ovarian cancer? J Clin Oncol 2008, 26(No 15S):20689.
26. Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported
questionnaire data: another step toward consensus. J Clin Epidemiol 2005,
58(12):1217-1219.
27. Queensland Centre for Gynecological Cancer. Outcome data statistical
report 2008.
28. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE,
Handman M: The group psychotherapy and home-based physical
Newton et al. BMC Cancer 2011, 11:389
http://www.biomedcentral.com/1471-2407/11/389
Page 8 of 9
exercise (Group-Hope) trail in cancer survivors: Physical fitness and
quality of life outcomes. Psycho-oncology 2003, 12:357-374.
29. Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB,
Steed H, Faught W, Courneya KS: Physical activity preferences of ovarian
cancer survivors. Psycho-oncology 2009, 18(4):422-428.
30. Joly F, Vardy J, Pintilie M, Tannock I: Quality of life and/or symptom
control in randomized clinical trials for patients with advanced cancer.
Ann Oncol 2007, 18:1935-1942.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/389/prepub
doi:10.1186/1471-2407-11-389
Cite this article as: Newton et al.: Safety, feasibility and effects of an
individualised walking intervention for women undergoing
chemotherapy for ovarian cancer: a pilot study. BMC Cancer 2011 11:389.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Newton et al. BMC Cancer 2011, 11:389
http://www.biomedcentral.com/1471-2407/11/389
Page 9 of 9
